Latest News

Morgan Stanley says flu vaccine data is likely to boost Moderna’s stock


Moderna’s phase 2 trial data for its flu vaccine is expected early this year and could push the stock higher.

Rio Tinto to Pay $7.7 Billion Dividend as Profit Hits Record

Previous article

Mortgage applications drop to lowest level in over 2 years

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News